CONTRACTING ORGANIZATION: Mount Sinai School of Medicine, New York, NY 10029

Similar documents
TITLE: Dietary Genistein and Prostate Cancer Chemoprevention

Fort Detrick, Maryland

CONTRACTING ORGANIZATION: University of California Lawrence Berkeley National Laboratory Berkeley, CA 94720

CONTRACTING ORGANIZATION: Western Institute For Biomedical Research Salt Lake City, UT

CONTRACTING ORGANIZATION: North Eastern Ohio Universities Rootstown OH 44202

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Award Number: W81XWH TITLE: Global Positioning Systems (GPS) Technology to Study Vector-Pathogen-Host Interactions

TITLE: 64Cu-DOTA-trastuzumab PET imaging in women with HER2 overexpressing breast cancer

TITLE: Neural Protein Synuclein (SNCG) in Breast Cancer Progression

TITLE: New Advanced Technology to Improve Prediction and Prevention of Type 1 Diabetes

Award Number: W81XWH

CONTRACTING ORGANIZATION: Johns Hopkins Bloomberg School of Public Health

CONTRACTING ORGANIZATION: Sloan-Kettering Institute for Cancer Research New York, NY 10021

Approved for public release; distribution unlimited

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Short-Term Exercise and Prostate Cancer Prevention in African American Men. CONTRACTING ORGANIZATION: Howard University Washington DC 20059

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

AD (Leave blank) Award Number: W81XWH TITLE: Targeting Autophagy for the Treatment of TSC and LAM. PRINCIPAL INVESTIGATOR: Elizabeth Henske

TITLE: Evaluation of DNA Methylation as a Target for Intraductal Therapy for Ductal Carcinoma in Situ of the Breast

TITLE: Post-Traumatic Headache and Psychological Health: Mindfulness Training for Mild Traumatic Brain Injury

Detection of Prostate Cancer Progression by Serum DNA Integrity

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: UNIVERSITY OF ILLINOIS Chicago, IL 60612

TITLE: Oxidative Stress, DNA Repair and Prostate Cancer Risk. PRINCIPAL INVESTIGATOR: Hua Zhao, Ph.D.

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Enhancing the Anti-Tumor Activity of ErbB Blockers with Histone Deaccetylase (HDAC) Inhibition in Prostate Cancer Cell Lines

TITLE: Targeting the Immune System s Natural Response to Cell Death to Improve Therapeutic Response in Breast Cancers

AWARD NUMBER: W81XWH TITLE: Treatment of Pain and Autonomic Dysreflexia in Spinal Cord Injury with Deep Brain Stimulation

TITLE: Computerized Tailored Interventions for Behavioral Sequelae of Post-Traumatic Stress Disorder in Veterans

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

AWARD NUMBER: W81XWH TITLE: Gulf War Illness as a Brain Autoimmune Disorder. PRINCIPAL INVESTIGATOR: Apostolos Georgopoulos, MD, PhD

AD (Leave blank) TITLE: Proteomic analyses of nipple fluid for early detection of breast cancer

TITLE: Genes Associated with Food Allergy and Eosinophilic Esophagitis

TITLE: Determination of Optimum Vitamin D Nutrition in Young Women. Omaha, NE 68178

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: Cold Spring Harbor Laboratory Cold Spring Harbor, NY 11724

Promote Adjustment during Reintegration following Deployment

CONTRACTING ORGANIZATION: Regents of the University of Michigan Ann Arbor, MI 48109

TITLE: Identification of New Serum Biomarkers for Early Breast Cancer Diagnosis and Prognosis Using Lipid Microarrays.

TITLE: Long Term Outcomes of BRCA1/BRCA2 Mutation Testing. CONTRACTING ORGANIZATION: Georgetown University Washington, DC

AD (Leave blank) TITLE: Trial of Naltrexone and Dextromethorphan for Gulf War Veterans Illnesses

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Award Number: W81XWH TITLE: "Longitudinal Study of a Novel Performance-based Measure of Daily Function."

Award Number: W81XWH

TITLE: MicroRNA in Prostate Cancer Racial Disparities and Aggressiveness

TITLE: Maximizing Energy After Traumatic Brain Injury: A Novel Intervention

TITLE: Effect of COX-2 (PGE2) and IL-6 on Prostate Cancer Bone Mets

AWARD NUMBER: W81XWH TITLE: Androgen Deprivation Therapy and Cognitive Impairment. PRINCIPAL INVESTIGATOR: Robert N. Pechnick, Ph.D.

TITLE: Mission Connect Mild TBI Translational Research Consortium. U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Prevention and Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors

CONTRACTING ORGANIZATION: Mount Sinai School of Medicine New York, New York

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: Oregon Health & Science University Portland OR 97239

AD (Leave blank) TITLE: Brief cognitive behavioral therapy for military populations

Sphingosine-1-Phosphate Receptor Subtype 3: A Novel Therapeutic Target of K-Ras Mutant Driven Non-Small Cell Lung Carcinoma

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: A Phase II Trial of Androgen Suppression and Radiation Therapy with Samarium-1 53 in Localized, High-Risk, Prostate Cancer

TITLE: Responsiveness of a Neuromuscular Recovery Scale for Spinal Cord Injury: Inpatient and Outpatient Rehabilitation

TITLE: Adipose Estrogen and Increased Breast Cancer Risk in Obesity: Regulation by Leptin and Insulin

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Page 1 AWARD NUMBER: W81XWH TITLE: A Novel Pleiotropic Anti-Inflammatory Drug to Reduce ARDS Incidence. PRINCIPAL INVESTIGATOR: Gary Nieman

TITLE: Estrogen-DNA Adducts as Novel Biomarkers for Ovarian Cancer Risk and for Use in Prevention

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Investigation of the Akt/PKB Kinase in the Development of Hormone-Independent Prostate Cancer

TITLE: Inhibitors of Histone Deacetylases for Radiosensitization of Prostate Cancer

TITLE: Properties of Leukemia Stem Cells in a Novel Model of CML Progression to Lymphoid Blast Crisis

TITLE: A Tissue Engineering Approach to Study the Progression of Breast Tumor Metastasis in Bone

TITLE: Gulf War Illness Evaluation of an innovative detoxification program

TITLE: Investigating the Role of TBX2 in the Inhibition of Senescence in Prostate Cancer

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, MD

TITLE: Breast Density Assessment by Dual Energy X-ray Absorptiometry in Women and Girls. Rachel Novotny, Ph.D. Honolulu, HI 96822

TITLE: Genetic and epigenetic biomarkers for recurrent prostate cancer after radiotherapy

CONTRACTING ORGANIZATION: University of Mississippi Medical Center Jackson, MS 39216

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Prostate Expression Databases: Gene Expression Resources for Comparative Studies of Prostate Carcinogenesis

TITLE: Effect of Reminder Telephone Calls on Mammography Compliance in High Risk

TITLE: TREATMENT OF ENDOCRINE-RESISTANT BREAST CANCER WITH A SMALL MOLECULE C-MYC INHIBITOR

Approved for public release; distribution unlimited

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: Memorial Sloan-Kettering Cancer Center New York, NY 10065

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer

TITLE: Role of ADAM15 in Tumor/Endothelial Interactions Prostate Cancer Regression

TITLE: Demonstrating the Efficacy of Group Prolonged Exposure Treatment of PTSD in OEF/OIF/OND Male Veterans

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Award Number: W81XWH TITLE: A Novel Membrane-Permeable, Breast-Targeting, Pro-Apoptotic Peptide for Treatment of Breast Cancer

RECIPIENT: Lankenau Institute for Medical Research, Wynnewood, PA 19096

Award Number: W81XWH TITLE: CYP1B1 Polymorphism as a Risk Factor for Race-Related Prostate Cancer

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: West Virginia University Morgantown, West Virginia

TITLE: The Role of HOX Proteins in Androgen-Independent Prostate Cancer

TITLE: Overcoming Resistance to Inhibitors of the Akt Protein Kinase by Modulation of the Pim Kinase Pathway

TITLE: Effects of Tobacco Smoke (TS) on growth of clear cell renal cell carcinoma (ccrcc)

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: The Role Of Alternative Splicing In Breast Cancer Progression

TITLE: Prazosin for Treatment of Patients With PTSD and Comorbid Alcohol Dependence

CONTRACTING ORGANIZATION: Spaulding Rehabilitation Hospital, Boston, MA 02129

TITLE: Interchromosomal Associations that Alter NF1 Gene Expression Can Modify Clinical Manifestations of Neurofibromatosis 1. Palo Alto, CA 94304

CONTRACTING ORGANIZATION: Joan & Sanford I. Weill Medical College of Cornell University New York, NY 10065

Transcription:

AD Award Number: W81XWH-11-1-0604 TITLE: An Intervention to Control Vasomotor Symptoms for Advanced PC Patients on Hormone Therapy PRINCIPAL INVESTIGATOR: Michael A. Diefenbach, Ph.D. CONTRACTING ORGANIZATION: Mount Sinai School of Medicine, New York, NY 10029 REPORT DATE: AUGUST 2012 TYPE OF REPORT: Annual Report PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE Form Approved OMB No. 0704-0188 Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. 1. REPORT DATE 2. REPORT TYPE 01-08-2012 Annual 4. TITLE AND SUBTITLE An Intervention to Control Vasomotor Symptoms for Advanced PC Patients on Hormone Therapy 3. DATES COVERED 15 July 2011 14 July 2012 5a. CONTRACT NUMBER 5b. GRANT NUMBER W81XWH-11-1-0604 5c. PROGRAM ELEMENT NUMBER 6. AUTHOR(S) Michael A. Diefenbach E-Mail: michael.diefenbach@mountsinai.org 5d. PROJECT NUMBER 5e. TASK NUMBER 5f. WORK UNIT NUMBER 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER Mount Sinai School of Medicine New York, NY 10029 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR S ACRONYM(S) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT During the past 12 months, we have received IRB approval from Mount Sinai School of Medicine, the James P. Peters VA Medical Center IRBs, and the Department of Defense. We have also held three focus groups with prostate cancer patients undergoing hormone therapy and multiple research team meetings were held to discuss focus group results, software development, and study protocol. We are currently integrating feedback from the final focus group into the vasomotor symptom intervention (VSI) and plan to run a final focus group to test the usability of the application. Our progress over the previous project period has led us to refine the methodology and software development, and this will allow us to begin the intervention phase during Y2 of the award. 15. SUBJECT TERMS Focus group, vasomotor symptom intervention, software development 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT a. REPORT U b. ABSTRACT U c. THIS PAGE U UU 6 18. NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area code)

TABLE OF CONTENTS SUMMARY..4

1 Project title: An Intervention to Control Vasomotor Symptoms for Advanced PC Patients on Hormone Therapy Principle Investigator: Michael A. Diefenbach Grant Number: PC101229 Date: 08/02/2012 Summary: Our study team has made great progress during the previous year of our study entitled An Intervention to Control Vasomotor Symptoms for Advanced PC Patients on Hormone Therapy. During the past 12 months, we have received IRB approval from Mount Sinai School of Medicine, the James P. Peters VA Medical Center IRBs, and the Department of Defense. We have also held three focus groups with prostate cancer patients undergoing hormone therapy and multiple research team meetings were held to discuss focus group results, software development, and study protocol. We are currently integrating feedback from the final focus group into the vasomotor symptom intervention (VSI) and plan to run a final focus group to test the usability of the application. Our progress over the previous project period has led us to refine the methodology and software development, and this will allow us to begin the intervention phase during Y2 of the award. Progress is described in more detail below. Task 1: Institutional Review Board Process Protocol and all required documents have been submitted to the Institutional Review Boards (IRB) of Mount Sinai School of Medicine s (MSSM) and the James. P. Peters VA Medical Center (JJP VAMC). After MSSM and James P. Peter VA Medical Center approved the protocols, all approved study materials were submitted to the Department of Defense s Institutional Review Board (IRB). Study personnel updated their required HIPPA and IRB training. In addition to the CITI training at MSSM, all personnel have obtained the following 1) HIPPA authorization, and 2) Privacy and Data Security of MSSM and JJP VAMC. All recruitment personnel have been trained to explain and to obtain informed consent from study participants. Task 2: Phase I of the software development In June of 2011, the Principle Investigator met with co-investigators (Dr. Nihal E. Mohamed, Dr. Simon Hall, and Dr. Tracey A. Revenson) and consultants (Kevin Durr, and Dr. William Dudley) to discuss contents of the ipod training, intervention and assessment modules. Based on this meeting we developed the script content and assessments for the vasomotor symptoms paced respiration training, intervention, and assessment modules. During subsequent meetings wire frames (i.e., prototypical mock-ups of the ipod software interface), which contain elements such as animation, music samples, voiceover, and selected actors have been discussed. A contractor composed a short piece of music that will assist with the correcet breathing rhythm. Short video clips were selected to illustrate the breathing pattern visually. Additional features of the software are its ability to track the frequency and duration of hot flashes and to let participants rate the severity of the hot flash they just experienced. A summary screen visualizes all recorded hot flashes within a given week.

2 Task 3: Refine and finalize Focus Group Guides Next, the team revised, expanded and finalized the focus group guide and its procedures. The revised guide was submitted and approved by all relevant IRBs. Results of the focus groups have informed the Vasomotor Symptom Intervention (VSI) adoption and its development process. Task 4: First set of 2 focus groups: preparation, conduct, and analyses Of the planned focus groups, the first two groups (n = xxx) would mainly focus on the nature of vasomotor symptoms (VS), severity, frequency and their impact on their daily lives. These first two focus groups also gauged the mens reaction to the breathing intervention techniques. Focus groups were conducted at the JJP VAMC. Men were African American, on average xxx years old, and have been on ADT an average of xxxx months. All suffered from hot flashes of various severities, ranging from mild to severe. The hot flashes were described by patients as being accompanied by profuse sweating, nausea, shivering, head warmth, and dizziness, among other symptoms. There was no consensus on what time of day the hot flashes occur, what may trigger them, and how long they last. While one patient experienced them every day at 5 AM, others say they happen all the time, and yet others claim that it changes every day and there are no specific triggers. Some patients experienced their hot flashes for no more than five minutes while others say they lasted between 10 and 15 minutes. All patients were excited about the potential of a non-pharmacological intervention for VS control. Task 5: Phase II of the software development The information from the first two groups was useful in developing the first prototype of the application. Because the duration of the hot flash varies within and between-subjects, this information will be recorded by the application and used for further analysis. When the patient is experiencing a hot flash and starts the paced respiration exercise with the help of the software the application will time how long the hot flash lasted and at what time it occurred. The software will also prompt the user to record how severe ( bad ) the hot flash was. This information will then be summarized on a chart for the patient s reference, allowing him to follow trends. Participants in the first two focus groups were also probed about the feasibility of using a breathing exercise application. We realized that men might not always use the software to control their hot flashes and thus we incorporated an additional feature into the application that allows users to record VS information once the hot flash is over. After the patient has experienced a hot flash, he can open the application and select I Had a Hot Flash, and enter the pertinent information into the application (i.e., time, intensity, and duration of the hot flash.) Task 6: Second set of 2 focus groups: preparation, conduct, and analyses The third focus group (n = 6) focused on contents and potential usability of the ipod-based VSI. Again, men were African American, recruited from JJP VAMC, who suffered from VS. We showed a comprehensive layout of the program, including all relevant screens, graphics, videos, and music clips. Participants at first examined the wireframes without further detailed explanation. Men were asked whether they could intuit the functions of different areas of the screen and queried how they would interact with the program. All patients grasped the design

3 and layout without problems. They stated preferences for certain graphics, videos, and music clips. Suggestions were also given for the distraction control group in which the participants will be given several options of games to play rather than the breathing exercise. All completed focus groups were transcribed for analysis and results were incorporated into the final version of the VSI. Results of this focus group were incorporated into the beta version of the study. Task 7: In Progress During July 2012 to August 2012, Kevin Durr and his development team will finish finalizing the ipod application. Twelve ipod Touches have been purchased in July 2012 and they are ready for the program to be installed. We expect to start identifying and recruiting participants for usability testing group from both MSSM and JJP VAMC (N=10) to conduct the Beta test early September 2012. All recorded sessions will be transcribed and data obtained from this phase will be used to implement final changes into ipod Touch VSI. During this time, personnel will be trained on the program, and assessment modules. By October 2012, we expect to begin the small randomized feasibility and acceptability trial.